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Abstract Paracoccidioidomycosis (PCM) is a sys-
temic granulomatous disease, endemic in Latin
America, caused by the thermal dimorphic fungus
Paracoccidioides brasiliensis. Although some fungal
antigens have already been characterized and used for
serological diagnosis, cross-reactions have been fre-
quently observed. Thus, the examination of fungal
forms in clinical specimens or isolation of P. brasil-
iensis by culture is still the most frequent method for
the diagnosis of this mycosis. In this study, a random
peptide phage display library was used to select
mimotopes of P. brasiliensis, which were employed
as antigens in an indirect enzyme-linked immunosor-
bent assay. The protective monoclonal antibody
against experimental PCM (anti-gp75) was used as
molecular target to screen a phage display library.
That approach led to a synthetic peptide named P2,
which was synthesized and tested against PCM
patients’ sera to check whether it was recognized.
There was signiﬁcant recognition of P2 by sera of
untreated PCM patients when compared with normal
human sera. Sera from treated PCM group, patients
with other mycosis or co-infected with HIV had much
lower recognition of P2 than untreated patient group.
The test showed a sensitivity of 100 and 94.59% of
speciﬁcity in relation to human sera control. These
data indicate a potential use of P2 as diagnostic tool in
PCM. Its application for serological diagnosis of PCM
may contribute to the development and standardiza-
tion of simpler, faster and highly reproducible immu-
nodiagnostic tests at low cost.
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Introduction
Paracoccidioides brasiliensis is the agent of paracoc-
cidioidomycosis (PCM), a prevalent disease in Latin
America. Despite the large number of cases frequently
diagnosed, the exact epidemiology of PCM is not
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tion of identiﬁed cases. Due to the lack of available
data, PCM was recently added to the list of neglected
diseases [1].
The infection probably begins by inhalation of
fungal propagules that, once in the lungs, transform
into the pathogenic yeast forms [2] with ability to
disseminate through the lymphatic system and the
bloodstream to any location in the host’s organism [3].
Two clinical forms of the PCM are recognized: acute
form (AF), which is more rare and severe, with
involvement of the reticuloendothelial system; and
chronic form (CF), which may develop in multiple
ways, ranging from benign and localized (unifocal) to
severe and disseminated (multifocal) disease, depend-
ing on the degree of depression of cellular immunity
[4, 5].
Regarding its diagnosis, serology has an important
role in identifying the suspected cases of PCM.
However, difﬁculties in the immunodiagnosis have
been associated with cross-reactions with antibodies
present in sera from patients with other mycosis or
diseases, mainly due to antigen preparation used [6].
To improve serodiagnosis of PCM, great efforts have
been made, such as using recombinant proteins [7, 8]
that in most cases, reduced cross-reaction [9]. Never-
theless,productionofthesemoleculesstillrepresentsa
high cost, being used only in research centers.
Considering that for PCM diagnosis, only the
epitopes able to induce speciﬁc humoral response
may be sufﬁcient in immunologic reactions, herein,
we employed the phage display methodology to deﬁne
peptides that mimic natural epitopes. It consists of a
collection of millions of randomized peptides dis-
played on bacteriophage surfaces that can be used to
identify ligands of molecules of interest [10–12].
Peptides that mimic epitopes (mimotopes) have been
identiﬁed by screening phage libraries with monoclo-
nal antibodies (mAb) in several models and those
synthetic peptides have been used for diagnostic
applications with promising results [13–16].
In thisstudy, aphage display approach was used for
the ﬁrst time to identify ligands mimicking antigenic
epitopes from P. brasiliensis. The protective mono-
clonal antibody 5E7C (anti-gp75) was used here to
select binding peptides [17]. After selection and
analysis procedures, one synthetic peptide selected
(called P2) was signiﬁcantly recognized by untreated
PCM patients’ sera when compared with controls.
These results open the way to new approaches using
peptides for the diagnosis of PCM.
Materials and Methods
Mice
Male BALB/c mice, 6–8 weeks old, were obtained
from the animal facility, Federal University of Sa ˜o
Paulo (UNIFESP), SP, Brazil. Animal handling and
housing were performed in accordance with the NIH
Guide for Care and Use of Laboratory Animals.
Bacterial Strain and Growth Conditions
The E. coli ER2738 strain was obtained from New
England Biolabs, Inc. (Beverly, Massachussets, USA)
exhibiting rapid growth and suited for propagation of
phages (M13). These bacteria have a mini-transposon
that confers tetracycline resistance. It was grown in
Luria–Bertani agar containing 20 lg tetracycline/mL
at 37C overnight with shaking.
Production of P. brasiliensis Exoantigen
All experiments were carried out with P. brasiliensis
yeast cells from isolate Pb18 kindly provided by Prof.
Vera L. G. Calich from the Department of Immunol-
ogy, Sa ˜o Paulo University. To obtain secreted protein
produced by P. brasiliensis, yeast cells cultured for
5 days in modiﬁed solid YPD [0.5% yeast extract
(Oxoid), 0.5% casein peptone (Difco), 1.5% glucose
(Synth) and 1.5% agar (Difco), pH 6.5] were trans-
ferred to Erlenmeyer containing 50 mL of modiﬁed
liquid YPD and maintained under agitation for 3 days
at 37C. Then, the fungal cells were transferred to
Fernbach ﬂask containing 450 mL of the same
medium and cultured for 7 days. The cells were killed
with 0.4 g/L of timerosal (Sigma), and the supernatant
(crude exoantigen) was collected by ﬁltration through
ﬁlter paper. The exoantigen protein content was
determined by the Bradford method [18], analyzed
by SDS–PAGE [19] and stored at -20C.
Preparation of Monoclonal Antibody (mAb)
Both 5E7C (anti-gp75) and 17C (anti-gp43) mAb [17,
20]were obtainedfromascitic liquid ofBALB/cmice.
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chromatographyofasciticﬂuidicinacolumnprepared
with Sepharose coupled with protein A (Pharmacia,
Uppsala, Sweden). The puriﬁed mAb was always
tested by immunoblotting to verify the recognition of
its speciﬁc proteins in P. brasiliensis exoantigen.
Phage Display Library
Experiments were performed with Ph.D.-7 library
(New England Biolabs, Inc., Beverly, Massachussets,
USA) that consisted of 1.2 9 10
9 independent clones.
This library contains peptide sequences (7-mer),
inserted into the NH3 terminus of the pIII minor coat
protein of the M13 bacteriophage. The randomized
segment of seven amino acids (CX7C–C, cysteine; X,
any aminoacid residue)isﬂankedby apair ofcysteine
residues, which are oxidized during phage assembly to
form a disulﬁde linkage. The ﬁrst residue of the
peptide–pIII fusion is the ﬁrst randomized position
thatisprecededbyAla–Cys.Theshortlinkersequence
(Gly–Gly–Gly–Ser) is localized between the dis-
played peptide and pIII. This speciﬁc library carries
the lacZa gene, and phage plaques appear blue when
plated on media containing Xgal and IPTG.
Selection of Binding Peptides by Phage Display
Selection was performed according to the manufac-
turer’s instructions (New England Biolabs, Inc.,
Beverly, Massachusetts, USA). First, library was
cleaned with mAb 17C (anti-gp43) that belongs to
the same isotype of the mAb 5E7C (IgG2a) to
eliminate non-speciﬁc phage clones to the target
molecule (mAb 5E7C). Brieﬂy, 100 lg/mL of mono-
clonalantibody17Cwasaddedintoallscreeningwells
of 96-well ELISA plate, and the plate was kept at 4C
overnight. The wells were blocked with blocking
buffer (0.1 M NaHCO3 [pH, 8.6], 5 mg/mL BSA,
0.02% NaN3)a t4 C for 60 min followed by six
washeswithTBS-T(TBS50 mM,Tris–HCl[pH,7.5],
150 mM NaCl—plus 0.1%, v/v; Tween-20). Next,
10
11 plaque-forming units (PFU) were added to each
well, and the plate incubated at room temperature for
1 h. The unbound phages remained in the supernatant
and were used for subsequent stages of selection of
5E7C ligand phage clones. Those phage clones were
ampliﬁed, titled in plates containing LB/IPTG/Xgal
medium and used for selection of 5E7C ligand phage
clones. The preselection-obtained phage clones were
incubated with 5E7C mAb adsorbed in ELISA plates
(100 lg/mL). All procedures of blocking and washing
wereperformedasdescribedabove.Phagesthatbound
to mAb 5E7C were eluted with glycine–HCl (0.2 M
[pH, 2.2], 1.0 mg/mL BSA) by gently rocking for
10 min and were then neutralized with 1 M Tris–HCl
(pH, 9.1) to pH 7. The phage solution was taken for
dilution with LB medium, and the title of the phages
was determined. Subsequently, the eluted phages were
ampliﬁed by infection of E. coli ER2738 and concen-
trated by precipitation with PEG/NaCl (20%, w/v
polyethylene glycol-8000, 2.5 M NaCl). The same
panning procedures were used to the second and third
generations, except for the washing step in which
Tween-20 0.5% (v/v) was used. After the third round
of panning, positive phage clones were selected.
DNA Sequencing
Phage clones were prepared for DNA sequencing as
described in the Ph.D 7-mer phage display peptide
library kit. The method used for the PCR product
sequencing was automatic, accomplished in the ABI
Prism 3100 Genetic Analyzer equipment, with the
commercial kit Big Dye Terminator 3.1 (Applied
Biosystems), according to the manufacturer’s instruc-
tions. Brieﬂy, 4.0 pmol of speciﬁc initiator oligonu-
cleotide (50-TAATAC GACTCAC TATAGG
GCAAGC TGATAA ACCGAT ACAATT-30),
1.5 lL of Big Dye Mix, 2 lL of sequencing buffer
(ﬁve times) and 4.5 lL of the puriﬁed samples for
sequencing were used. The thermocycling program
used 34 cycles, with denaturation at 96C for 10 s,
annelation at 50C for 5 s and extension at 60C for
4 min. The DNA was precipitated (for 15 min at
25C) with addition of 40 lL of ethanol 80% (Merck)
following centrifugation with 4,000 rpm for 1 h at
25C. After discarding the supernatant, all samples
werewashedwith150 lLofethanol70%(Merck)and
re-suspended in 10 lL of HiDi formamide (Applied
Biosystem). Samples were denatured at 90C for
2–5 min and immediately placed in ice.
Graphic Analyses of Antigenicity and Structural
Parameters of the Peptides Sequences
The sequences of peptides selected were analyzed by
Jameson-Wolffantigenicindexmethods,Kyte-Doolittle
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pathic regions, Emini’s and motifs surface probability
plot and Sette major histocompatibility complex II
[21–23] using the Protean program (protein sequence
analysis) of Lasergene biocomputing for Windows,
1994 (DNASTAR Inc., Madison, Wisconsin, USA).
Binding
The interaction between the selected phage clones and
the 5E7C mAb was evaluated by in vitro binding
assays. The phage clones selected were incubated in
96-well plates previously sensitized with 100 lg/mL
of each mAb (17C, anti-gp43 or 5E7C, anti-gp75).
After blocking with blockage buffer, wells were
washed six times with TBST 0.1%. Selected phage
clones (2 9 10
11 of each) were diluted in TBST 0.1%
(ﬁnal volume of 100 lL) and added to sensitizedwells
with mAbs. After 2 h of incubation at room temper-
ature, the wells were washed 10 times with TBST
0.1%, and phage clones bound to the antibody were
eluted, as described above. Phages eluted were
recovered through infection in E. coli ER2738. Serial
dilutions were prepared, and the bacteria were plated
in LB IPTG/Xgal medium for quantiﬁcation of the
number of bound phage clones.
Peptide Synthesis
Peptides were kindly synthesized by Maria Aparecida
Juliano at the facility of Department of Biophysics,
Federal University of Sa ˜o Paulo (UNIFESP), SP,
Brazil. The 9-ﬂuorenylmethoxycarbonyl method [24]
was performed using an automated benchtop simulta-
neous multiple solid-phase peptide synthesizers
(PSSM 8 system; Shimadzu, Tokyo, Japan).
Animal Immunization Using Synthetic Peptides
Groupof5BALB/cmicewasimmunizedfourtimesat
10 days intervals with 20 lg of synthetic peptide. The
ﬁrst immunization was performed with emulsiﬁed
peptide in complete Freund’s adjuvant (CFA) and the
subsequent immunizations with incomplete Freund’s
adjuvant (IFA). The emulsion (50 lL) was subcuta-
neously inoculated in the footpad. Control mice
received only adjuvant. Before each immunization,
blood samples were collected by the ocular plexus and
the serum was separated and kept at -20C.
Immunoblotting
Proteins of exoantigen from P. brasiliensis were
fractionated by sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS–PAGE) under reduc-
ing conditions [19]. The proteins were transferred to
nitrocellulose (NC) membranes [25], and non-speciﬁc
siteswereblockedwithPBScontaining5%skimmilk.
Sera from P2 peptide-immunized animals were added
to each NC strips for 1 h at room temperature. Strips
were washed ﬁve times for 5 min each with PBS
containing 0.1% Tween 20. After treatment with
afﬁnity-puriﬁed peroxidase-conjugated goat anti-
mouse immunoglobulin (Ig) (Zymed) for 1 h at room
temperature, the reactive Ig was detected by ECL
detection reagent (GE Healthcare, UK).
Human Serum Specimens
Individual serum specimens from 33 individuals with
acute or chronic localized PCM and 31 treated PCM
patients were obtained from Sa ˜o Paulo Hospital (Sa ˜o
Paulo, Brazil). All patients’ sera were positive for
whole exocellular P. brasiliensis antigens by immu-
nodiffusion test. Untreated refers to patients under
treatment with antifungal drugs. All patients in this
group had low titers by immunodiffusion.
Control sera from healthy blood donors (n = 37)
and sera from patients with aspergillosis (Asp, n = 8),
histoplasmosis (HC, n = 17) and candemia (CA,
n = 20) were kindly provided by Medical Mycology
laboratory from Federal University of Sa ˜o Paulo. Prof.
RobertoMartinez, Faculdade de Medicina de Ribeira ˜o
Preto Universidade de Sa ˜o Paulo, kindly provided
sera from patients co-infected with HIV and PCM
(n = 10), and HIV and histoplasmosis (n = 10). Sera
from individuals infected with other mycosis were
negative against P. brasiliensis antigens by immuno-
diffusion. This study was approved by the Research
Ethics Committee (CEP) of UNIFESP with protocol
number 0484/07.
Detection of Human Serum Antibodies Against P2
Peptide
ELISA was carried out to detect circulating antibodies
that recognized P2 peptide in PCM patients’ sera.
First, 96-well polyvinyl plates (Costar) were sensi-
tized with 50 lg/mL of P2 diluted in PBS (50 lL/
4 Mycopathologia (2012) 174:1–10
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were blocked with 200 lL of PBS-molico 5% for 1 h
at 37C. Then, wells were washed three times with
PBS-molico 5% containing Tween 0.1%. Patients’
sera were added at dilution 1:20 in PBS-Molico 5%
(50 lL/well) for 1 h at 37C. Following, wells were
washed with PBS-molico 5% containing Tween 0.1%
(200 lL/well), and anti-IgG human secondary anti-
body coupled to the peroxidase (Sigma) diluted at
1:1,000 in PBS-molico 5% was added in each well.
The reactive sera were detected by addition of
substrate solution (1 mg of o-phenylenediamine
[OPD] in 5 mL of 0.1 M citrate–phosphate buffer
[pH, 5.0] plus 10 lL of 30% H2O2), and the reaction
interrupted by the addition of 50 lLo f4NH 2SO4 per
well. Optical density was measured in an automatic
MCC/40 reader (Labsystem Multiscan Dynatech,
Chantilly, Virginia, USA) at 492 nm.
Statistical Analysis
The statistical analyses were accomplished by the
Student’s t test using the INSTAT program (GraphPad
4.0, San Diego CA) or by analysis of variance
(ANOVA) followed by the Tukey–Kramer test.
P\0.05 indicated statistical signiﬁcance. The cutoff
was determined by receiver operating characteristic
(ROC) curve.
Results
Selection of Phages Displaying Peptides
Recognized by Anti-gp75 Antibodies
The speciﬁcity of anti-gp75 (5E7C) and anti-gp43
mAbs (17C) was checked as shown in Fig. 1a.
Figure 1b shows the enrichment of the phages after
selection cycles. The amount of phages recovered was
4.2 9 10
11 and 8.9 9 10
11 pfu/mL in the ﬁrst and
second rounds (Fig. 1b), respectively. After the third
round, in which more stringent conditions were used,
1.8 9 10
11 phage clones were obtained. These results
indicate the presence of clones bearing the peptide
sequence recognized by 5E7C.
Phages displaying peptide sequences that mim-
icked the epitope of the 75-kDa protein of P.
brasiliensis were analyzed, and the peptides P9, P13,
P18, P19, P25 and P36 were selected for further
studies. Table 1 shows the sequences of selected
peptides.
Binding assays were performed to evaluate the
interaction between the selected phages (P9, P13, P18,
P19, P25 and P36) and mAb 5E7C. As shown in the
Fig. 1c, phages displaying P9, P18, P19, P25 and P36
bound with similar patterns to both 5E7C and 17C
mAbs.Ontheotherhand,phagespresentingP13peptide
signiﬁcantly bound to the 5E7C monoclonal antibody
whencomparedwithanti-gp43mAb.Thesedatasuggest
thatthepeptidesequenceexpressedbyP13seemedtobe
themostpromisingcandidatetobeamimotopeforanti-
gp75 mAb and was chosen for more detailed analysis.
P2 Synthetic Peptide Construction and Analyses
of Antigenic and Structural Parameters
Considering that gp75 immunopuriﬁed with 5E7C
showed phosphatase activity in vitro [17], the P13
cyclic peptide (CHSSLLNPC) selected by phage
display against 5E7C was aligned and analyzed with
phosphatasessequencesdepositedinthedatabaseofP.
brasiliensis genome project (http://www.broad.mit.
edu/annotation/genome/paracoccidioides_brasiliensis/
MultiHome.html)(datanotshown).Besides,aimingto
improve the antigenic potential of the peptide selected
sequence, ﬁve amino acids similar to the phosphatase
sequence showing greater homology were added to
the N-terminal and C-terminal, ﬂanking the initial
sequence of nine amino acids. Using this approach,
two sequences of peptides were obtained: NAN-
EAHSSLLNNALSI(P2)andDEHSRSLLNPRQETW
(P5). Figure 2a shows graphic analyses of the anti-
genic and structural parameters of the P2 and P5
sequences. As observed, P2 peptide sequence pre-
sented highest antigenic indexes and hydrophilicity
proﬁles and therefore was selected to be synthesized
and used in subsequent experiments.
By ELISA, P2 peptide was recognized by 5E7C
mAb mainly at the lower dilutions of the ﬂuid ascitic
containing anti-gp75 mAb. These data are strong
evidence that P2 synthetic peptide may represent a
mimotope of gp75.
Evaluation of Antigenic Potential of P2
Humoral immune response induced by P2 synthetic
peptide was evaluated by subcutaneous immuniza-
tion of BALB/c mice. After three immunizations,
Mycopathologia (2012) 174:1–10 5
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Serial dilutions of a pool of sera from mice after the
last immunization were employed, and the recognition
of P2 by polyclonal sera was observed (Fig. 3a). Sera
from control mice injected only with adjuvant did not
react with P2 synthetic peptide.
Anti-P2 polyclonal antibodies were recognized by
immunoblotting a band of 75 kDa in P. brasiliensis
exoantigen (Fig. 3b). This result is further evidence
that P2 synthetic peptide presented characteristics of a
mimotope of gp75.
Recognition of P2 Synthetic Peptide by PCM
Patients’ Sera
Given that previous works showed that infected mice
seraandPCMpatients’serareactwithabandof75 kDa
Fig. 1 Selection of the gp75 mimotope. a Immunoblotting
showing the speciﬁc recognition of anti-gp43 and anti-gp75
mAbs against exoantigen proteins. The puriﬁed anti-gp43 mAb
was used at 1:50 dilution. The anti-gp75 mAb was diluted at
1:400 (lane 1), 1:200 (lane 2), 1:100 (lane 3) or 1:50 (lane 4).
b Monitoring of speciﬁc phages to anti-gp75 mAb during three
rounds of biopanning. c Binding assay showing that phage
displaying P13 is a putative mimotope to anti-gp75 mAb.
PhagespresentingP9,P13,P18,P19,P25andP36peptideswere
incubated with 5E7C or 17C mAbs (negative control). Phages
that bound to those antibodies were recovered through infection
in E. coli ER2738. After incubation in LB IPTG/Xgal medium,
they were quantiﬁed. It is observed that only the P13 phage
clone speciﬁcally bound to mAb 5E7C when compared with
anti-gp43 mAb (P\0.05). Statistical analysis were performed
with Student’s t test (P\0.05)
Table 1 Amino acid sequences of peptide inserts identiﬁed
with the anti-gp75 antibody
Phage clones Peptide sequences
P9 CHMRNTIHC
P13 CHSSLLNPC
P18 CNSKLHAFC
P19 CYNPRLHIC
P25 CMEPKSRYC
P36 CSNRMATTC
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hypothesisthatP2peptidemayrepresentamimotopeof
gp75,weaskedwhetherP2peptidecouldberecognized
by PCM patients’ sera. In this proposal, ELISA was
developed using P2 as antigen. Figure 4 shows that
there was recognition of P2 peptide by sera from PCM
untreated individuals. On the other hand, there was no
reactionwithserafromnormalindividuals(NHS)when
comparedwithtreatedpatients (P\0.005).Thecutoff
was estimated by the ROC curve, and the value
determined by this method was 0.4233. The sensitivity
was 100% and speciﬁcity 94.59%.
When sera from treated PCM patients were tested,
no signiﬁcant recognition to P2 peptide was deter-
mined, considering the established cutoff. The mean
reaction of treated group was lower than untreated
group (P\0.005). Sera from patients co-infected
with HIV and PCM also did not recognize the peptide,
probably due to the impaired immune response
presented by these individuals. Nevertheless, one of
the sera tested showed high reactivity to P2 peptide
with an average OD of 1.729.
To verify the recognition of P2 by sera from
patients infected with other mycosis, we tested sera
from patients with candidemia, histoplasmosis, asper-
gillosis or co-infected with HIV and histoplasmosis.
Most sera were below the cutoff line; however, eight
sera from patients with histoplasmosis and four sera
from patients with candidemia showed cross-reaction
against P2, suggesting that epitope P2 may be shared
by proteins from other fungi.
Discussion
The diagnosis of PCM is considered technically
simple, and techniques are basically conventional
methodology such as the identiﬁcation of yeast cells
byhistopathology,isolatingofthefungusbycultureor
by detection of antibody in clinical samples [28].
However, none of the methods presently used is
sufﬁciently fast, cheap, sensitive or speciﬁc.
The gold standard of PCM diagnosis is the
demonstration of the parasite with morphological
Fig. 2 Analysis of antigenicity, structure and speciﬁcity of the
synthetic peptides obtained by phage display. a Analysis of P2
or P5 sequences. a Kyte-Doolittle hydrophilicity plot; b the red
box detaches the Eisenberg alpha amphipathic regions, the
green correspond to Eisenberg beta amphipathic and the blue
shows Karplus-Schulz rexible regions; c Jameson-Wolff
antigenic index; and d Emini surface probability plot. Positive
values correspond to the hydrophilic structure. b The reactivity
of 5E7C to P2 peptide was evaluated by ELISA. The ascitic
liquid containing mAb was submitted to serial dilution starting
at 1:50. (Color ﬁgure online)
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clinical specimens [29]. Nevertheless, the direct
mycologicaldiagnosisdemands anexperiencedexam-
iner anddepends bothon the sample qualityand on the
reasonable amount of fungi in the preparation.
Another disadvantage is the time of fungus growth,
which is often slow. Therefore, to shorten the time
needed and diminish the material required to perform
these techniques, serological tests have been devel-
oped to detect both antibodies [30, 31] and antigens
[32–34]. Moreover, serological tests are important
tools either when other procedures are not available or
for post-therapy follow-up [9, 35].
Immunodiffusion (ID) is the most common method
employed for being simple, inexpensive and useful to
monitor the disease treatment. However, its very low
sensitivity leads to false-negative results and may not
exclude the possibility of PCM. Sensitive tests, like
ELISA and Western blot, increase the sensitivity of
immunological methods for diagnosis [36], but their
speciﬁcity depends on the nature of antigen used.
Speciﬁcally in PCM, most serologic diagnostic assays
use crude antigenic preparations that are not com-
pletely standardized. This fact is possibly responsible
for cross-reactions with other infections, mainly
histoplasmosis and Jorge Lobo0s disease [37].
Production of good antigenic preparations has
improved speciﬁcity and sensitivity in serological
tests.Thus,somepuriﬁedantigensfromP.brasiliensis
were characterized and used for antibody detection.
Among those antigens, gp43 is the most important
component studied [38]. The antigen is recognized by
virtually 100% of PCM patients’ sera [26], but its
carbohydrate composition contains epitopes recog-
nized by heterologous sera, mainly by histoplasmosis
Fig. 3 Antigenic potential of P2. a Five BALB/c mice were
immunized with P2 peptide emulsiﬁed in adjuvant. Fifteen days
after last immunization, ELISA was performed to verify the
production of polyclonal antibodies by animals. The sera of
immunizedmicereactedwithP2,showingantigenicpotentialof
synthetic peptide. b Recognition of gp75 by anti-P2 polyclonal
antibodies. Nitrocellulose membrane with exoantigen proteins
immobilized on the surface was tested with anti-P2 polyclonal
antibodies. The band with molecular weight of 75 kDa was
recognized by sera containing anti-P2 antibodies. Anti-gp43
were used as reaction control
Fig. 4 Recognition of P2 synthetic peptide by serum of PCM
patients. Sera of untreated PCM patients (n = 33), treated PCM
patients (n = 31), patients co-infected with HIV and PCM
(n = 10), patients co-infected with HIV and HC (n = 10),
aspergillosis (Asp, n = 8), histoplasmosis (HC, n = 17),
candidemia (n = 24) and human normal serum (NHS,
n = 37) were tested to verify the reactivity against P2 peptide.
Untreated PCM group signiﬁcantly recognized P2 as compared
with other groups (P\0.005). ANOVA was followed by the
Tukey–Kramer test
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medium, but its puriﬁcation depends on speciﬁc mAb
[20] or HPLC systems [39], limiting its production to
referral centers and/or research.
Importantly, the application of new methods for
obtaining antigens able to improve serological diag-
nosisofPCM,suchasproductionofsyntheticpeptides
andrecombinantproteins,hasbeenrare.Herein,anew
approach was employed to prepare synthetic peptides
usefulforstandardizationofserologicaltestsforPCM.
A phage display library was used to select phage
clones that speciﬁcally bound to anti-gp75 mAb.
Resulting phages were analyzed, and promising can-
didates were tested by binding assays. Phage display-
ing a peptide, here named P13, signiﬁcantly bound to
the 5E7C monoclonal antibody (Fig. 1c). Its sequence
was aligned with sequences of phosphatases contained
in the P. brasiliensis genome databases in order to
improve the antigenic potential of the P13 peptide
sequence. Five amino acids corresponding to the
phosphatase sequence most homologous in portions N
and C-terminals were added ﬂanking the initial
sequence of nine amino acids, and the peptide
obtained was called P2. Our results showed that there
was a signiﬁcant recognition of P2 by untreated PCM
patients’ sera (acute or chronic forms) when compared
with control NHS (Fig. 4). It must be stressed that so
far, no synthetic peptide has been used for serological
diagnosis of PCM. P2 may be the ﬁrst with those
characteristics and thus be considered a promising
alternative to standardize serology for this endemic
mycosis in Latin America.
This work points the relevant advances and appli-
cations of a synthetic peptide (P2) on immunodiagno-
sis of PCM. The chemical imitation of antigens offers
possibilities in the diagnosis of parasitic infections
since this strategy is cheaper, simpler, reproducible,
useful for large scale testing and, in most cases,
speciﬁc and sensitive. Another advantage would be a
better standardization of tests among laboratories.
Thus, the same antigen could be used in all tests to
avoid possible variations in protein production of
exoantigen, inherent to the fungus and the different
culture media and growth conditions. Still, synthetic
peptides can be linked to beads to make a rapid test
with latex. This speciﬁc new approach has been
studied in our laboratory with promising results.
Currently, studies using large sample of patients’
serum have been conducted to determine sensitivity
and speciﬁcity of serological methods using P2 as
antigen. These tests are important and fundamental for
evaluation of its applicability on serodiagnosis of
PCM. Probably, a little engineering in P2 peptide may
be employed to improve its recognition by PCM
patients’ sera and/or virtually eliminate some cross-
reactions with sera from patients with other deep
mycoses. Moreover, the approach applied in this work
can be used to obtain different peptides applicable not
only to diagnosis, but also for immunization and/or
treatment of PCM.
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